European Investor
04 Aug 2026, 14:19
Vertex Pharmaceuticals Stock Rises 2.2% After Strong Q2 Results and Higher Revenue Guidance
Vertex Pharmaceuticals (NASDAQ: VRTX) shares rose 2.2% on Tuesday after the biotechnology company reported strong second-quarter results, raised its full-year revenue guidance and highlighted continued progress across both its commercial portfolio and late-stage pipeline.
Second-quarter revenue increased 12% year over year to $3.33 billion, driven by continued strength in its cystic fibrosis (CF) franchise and growing contributions from newer products, including CASGEVY and JOURNAVX. The company also increased its 2026 revenue outlook to $13.1 billion-$13.2 billion from its previous guidance of $12.95 billion-$13.1 billion.
Cystic Fibrosis Business Remains the Growth Engine
Vertex's core CF business continued to deliver solid performance, supported by strong patient demand for ALYFTREK and TRIKAFTA. U.S. revenue increased 11% to $2.06 billion, while international revenue rose 14% to $1.28 billion as ALYFTREK adoption expanded across global markets and CASGEVY infusions continued to grow.
Management expects non-CF products, primarily CASGEVY and the recently launched acute pain treatment JOURNAVX, to generate at least $500 million in revenue during 2026, reflecting the company's ongoing diversification beyond its traditional CF franchise.
Pipeline Expansion and Crinetics Acquisition Strengthen Outlook
Vertex continued advancing its pipeline, with povetacicept remaining on track for a November 30 PDUFA date. The company also announced its planned acquisition of Crinetics Pharmaceuticals, expected to close during the third quarter, adding rare endocrine diseases as a fifth major therapeutic pillar.
CEO Reshma Kewalramani said the company's expanding commercial portfolio and pipeline position Vertex to deliver additional innovative therapies while creating long-term shareholder value.
Strong Balance Sheet Supports Growth Strategy
Vertex ended the quarter with $13.6 billion in cash, cash equivalents and marketable securities, up from $12.3 billion at year-end, supported by strong operating cash flow. The company continued investing in commercial launches and pipeline development while repurchasing shares under its existing buyback program.
What to Watch
Investors will be watching the continued global rollout of ALYFTREK, commercial adoption of CASGEVY and JOURNAVX, the upcoming FDA decision on povetacicept, and the expected completion of the Crinetics acquisition. Markets will also monitor whether Vertex can continue expanding beyond cystic fibrosis while maintaining its strong revenue growth and profitability.
Vertex Pharmaceuticals (NASDAQ: VRTX) shares rose 2.2% on Tuesday after the biotechnology company reported strong second-quarter results, raised its full-year revenue guidance and highlighted continued progress across both its commercial portfolio and late-stage pipeline.
Second-quarter revenue increased 12% year over year to $3.33 billion, driven by continued strength in its cystic fibrosis (CF) franchise and growing contributions from newer products, including CASGEVY and JOURNAVX. The company also increased its 2026 revenue outlook to $13.1 billion-$13.2 billion from its previous guidance of $12.95 billion-$13.1 billion.
Cystic Fibrosis Business Remains the Growth Engine
Vertex's core CF business continued to deliver solid performance, supported by strong patient demand for ALYFTREK and TRIKAFTA. U.S. revenue increased 11% to $2.06 billion, while international revenue rose 14% to $1.28 billion as ALYFTREK adoption expanded across global markets and CASGEVY infusions continued to grow.
Management expects non-CF products, primarily CASGEVY and the recently launched acute pain treatment JOURNAVX, to generate at least $500 million in revenue during 2026, reflecting the company's ongoing diversification beyond its traditional CF franchise.
Pipeline Expansion and Crinetics Acquisition Strengthen Outlook
Vertex continued advancing its pipeline, with povetacicept remaining on track for a November 30 PDUFA date. The company also announced its planned acquisition of Crinetics Pharmaceuticals, expected to close during the third quarter, adding rare endocrine diseases as a fifth major therapeutic pillar.
CEO Reshma Kewalramani said the company's expanding commercial portfolio and pipeline position Vertex to deliver additional innovative therapies while creating long-term shareholder value.
Strong Balance Sheet Supports Growth Strategy
Vertex ended the quarter with $13.6 billion in cash, cash equivalents and marketable securities, up from $12.3 billion at year-end, supported by strong operating cash flow. The company continued investing in commercial launches and pipeline development while repurchasing shares under its existing buyback program.
What to Watch
Investors will be watching the continued global rollout of ALYFTREK, commercial adoption of CASGEVY and JOURNAVX, the upcoming FDA decision on povetacicept, and the expected completion of the Crinetics acquisition. Markets will also monitor whether Vertex can continue expanding beyond cystic fibrosis while maintaining its strong revenue growth and profitability.
